Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...
Telomir Pharmaceuticals, Inc. TELO on Thursday said the U.S. Food and Drug Administration (FDA) has cleared its ...
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results